Posted by Michael Wonder on 13 Dec 2022
Galera submits new drug application for avasopasem for severe oral mucositis
12 December 2022 - NDA based on two positive randomised, double-blinded, placebo-controlled trials which enrolled a total of 678 patients.
Galera Therapeutics today announced the submission of its new drug application to the US FDA for avasopasem for radiotherapy-induced severe oral mucositis in patients with head and neck cancer undergoing standard of care treatment.
